Doc said "Only a sociopath can work in mass therapy".

Published Date: 02 Mar 2023

Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.

Read Full News

Todays Updates


AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal


Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Upadacitinib After TNF Inhibitor Failure Improves RA Control


In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

AAN 2026: Key RRMS Clinical Trial Updates


Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.

Are Smartwatches Changing Arrhythmia Care?


Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.

Why the FDA Rejected RP-1 in Melanoma: A Data Deep Dive


Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.

Differential Diagnosis of Suspected Pulmonary Fibrosis and Efficacy of Approved Therapies


Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.

‘Living’ Database Tracks Psilocybin Trials for Depression


Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.

Todays Updates


AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal


Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Upadacitinib After TNF Inhibitor Failure Improves RA Control


In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

AAN 2026: Key RRMS Clinical Trial Updates


Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.

Are Smartwatches Changing Arrhythmia Care?


Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.

Why the FDA Rejected RP-1 in Melanoma: A Data Deep Dive


Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.

Differential Diagnosis of Suspected Pulmonary Fibrosis and Efficacy of Approved Therapies


Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.

‘Living’ Database Tracks Psilocybin Trials for Depression


Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

3.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

4.

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

5.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot